<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03362866</url>
  </required_header>
  <id_info>
    <org_study_id>2016/CHU/14</org_study_id>
    <nct_id>NCT03362866</nct_id>
  </id_info>
  <brief_title>Epidemiology of Hepatitis B, C and Delta in Reunion Island</brief_title>
  <acronym>HEPEPID</acronym>
  <official_title>Epidemiology of Hepatitis B, C and Delta in Reunion Island</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de la Réunion</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de la Réunion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Viral hepatitis B, C and Δ represent a global public health problem for which France was very
      early mobilized. Despite this, in its foreword, the Dhumeaux report on &quot;Management of people
      infected with hepatitis B or hepatitis C viruses&quot; identifies a residual area of weakness in
      this care that is the incomplete regional epidemiological data in the Overseas Territories.
      The specific ethno-socio-cultural characteristics of these territories make it difficult to
      transpose data from the mainland France. This study aims at improving our knowledge on the
      characteristics of patients with hepatitis B, C and Δ in Reunion Island, their follow-up,
      their evolution and complications.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with hepatitis B, C and Δ in Reunion</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Hepatitis diagnosis will be made according to the ongoing guidelines in France (referred by the National AIDS and Hepatitis Research Agency (ANRS)</description>
  </primary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Hepatitis C</condition>
  <condition>Hepatitis D</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Hepatitis B, C, D patients in Reunion Island
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Major patient

          -  with confirmed HBsAg and / or anti HCV positive Ab

          -  residing in Reunion Island

          -  followed in one of the participating centers

        Exclusion Criteria:

        • Patient carrying isolated anti HBc antibodies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier Maillard, PharmD</last_name>
    <phone>+262693025589</phone>
    <email>olmaillard@yahoo.fr</email>
  </overall_contact>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2017</study_first_submitted>
  <study_first_submitted_qc>November 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis D</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

